---
figid: PMC11860879__fimmu-16-1542326-g001
figtitle: Signaling pathways in the immune TME in AOC
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11860879
filename: fimmu-16-1542326-g001.jpg
figlink: /pmc/articles/PMC11860879/figure/F1/
number: F1
caption: Signaling pathways in the immune TME in AOC. The JAK2/STAT3 signaling pathway
  upregulates PD-L1 expression and enhances T cell immune escape. WNT/β-catenin signaling
  pathway increases VEGF-A expression and activates the M2-TAMs. NF-κB signaling pathway
  and CD39/CD73 activate MDSCs by promoting the secretion of cytokines CXCL2 and adenosine,
  respectively. MDSCs release TGF-β to inhibit NK cells. Tregs are activated by NF-κB
  signaling pathway and PI3K/Akt signaling pathway, all of which inhibit DCs and CTL
papertitle: 'A new strategy for the treatment of advanced ovarian cancer: utilizing
  nanotechnology to regulate the tumor microenvironment'
reftext: Zixuan Xiong, et al. Front Immunol. 2025;16(NA).
year: '2025'
doi: 10.3389/fimmu.2025.1542326
journal_title: Frontiers in Immunology
journal_nlm_ta: Front Immunol
publisher_name: Frontiers Media SA
keywords: advanced ovarian cancer (AOC) | tumor microenvironment (TME) | chemo-immunotherapy
  | drug resistance | nanotechnology
automl_pathway: 0.8857333
figid_alias: PMC11860879__F1
figtype: Figure
redirect_from: /figures/PMC11860879__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11860879__fimmu-16-1542326-g001.html
  '@type': Dataset
  description: Signaling pathways in the immune TME in AOC. The JAK2/STAT3 signaling
    pathway upregulates PD-L1 expression and enhances T cell immune escape. WNT/β-catenin
    signaling pathway increases VEGF-A expression and activates the M2-TAMs. NF-κB
    signaling pathway and CD39/CD73 activate MDSCs by promoting the secretion of cytokines
    CXCL2 and adenosine, respectively. MDSCs release TGF-β to inhibit NK cells. Tregs
    are activated by NF-κB signaling pathway and PI3K/Akt signaling pathway, all of
    which inhibit DCs and CTL
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL6
  - IL6ST
  - NM
  - LRPPRC
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - TNF
  - TNFRSF1B
  - TRAF2
  - TANK
  - BMX
  - EPHA3
  - JAK2
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - STAT3
  - AKT1
  - AKT2
  - AKT3
  - TAM
  - STIM1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AKAP6
  - MAK
  - ALPK3
  - NAA10
  - CTLA4
  - HLA-C
  - CD80
  - NFKB1
  - LEF1
  - TCF7
  - TCF7L1
  - TCF7L2
  - ATP8A2
  - CD86
  - ENTPD1
  - WDTC1
  - CD28
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - AMD1
  - AMD1P2
  - NT5E
  - CXCL2
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - TGFB1
  - TGFB2
  - TGFB3
  - DCs
  - ATP
  - Nucleus
  - ADP
  - AMD
  - cancer
  - Ovarian cancer
---
